Abstract
Response to chemotherapy was evaluated in 50 previously untreated patients with bony metastases of breast cancer. Lytic metastases respond in a definite sequence: sclerotic rim, filling-in, uniformly blastic, uniform fading. Increase in size of lytic areas or destruction in previously responding areas signals worsening. Mixed metastases are considered as beginning with a sclerotic rim. Response is otherwise similar. Particular attention is paid to the lytic areas. Blastic metastases are considered as beginning at the uniformly blastic stage. Progression is marked by a volumetric increase in blastic change or destruction in blastic regions. Change occurs slowly. Review of multiple studies is often necessary to reach the correct conclusion and clinical history is necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adair FE (1932) The treatment of metastatic and inoperable mammary cancer: With a discussion of certain distinct types of metastasis. AJR 27:517
Alexander JL, Gillespie PJ, Edelstyn GA (1976) Serial bone scanning using technetium 99m diphosphonate in patients undergoing cyclical combination chemotherapy for advanced breast cancer. Clin Nucl Med 1:13
Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgness MA, Livingston RB, Hersh EM (1980) Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer 45:742
Bouchard J (1945) Skeletal metastases in cancer of the breast: Study of the character, incidence and response to roentgen therapy. AJR 54:156
Carbone PP, Davis TE (1978) Medical treatment for advanced breast cancer. Semin Oncol 5:417
Citrin DL, Tuohy JB, Bessent RG, Greig WR, Blumgart LH (1974) Quantitative bone scanning: A method for assessing response of bone metastases to treatment. Lancet 1:1132
Frankel RS, Levenson SM (1975) Skeletal scintigraphy. In: Johnston GS, Jones AE (eds) Breast cancer diagnosis. Plenum Medical Book Company, New York London p 65
Galasko CSB, Doyle FH (1972) The response to therapy of skeletal metastases from mammary cancer: Assessment of scintigraphy. Br J Surg 59:85
Hayward JL, Rubens RD, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A (1977) Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292
Hayward JL, Rubens RD, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A (1978) Assessment of response to therapy in advanced breast cancer (an amendment). Br J Cancer 38:201
Hortobagyi GN, Glumenschein GR, Tashima CK, Buzdar AU, Burgness MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979) Ftorafur, adriamycin, cyclophosphamide, and BCG in the treatment of metastatic breast cancer. Cancer 43:398
Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979) Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide and BCG. Cancer 43:1225
Loeffler RK, DiSimone RN, Howland WJ (1975) Limitations of bone scanning in clinical oncology. JAMA 234:1228
Lokich JJ (1978) Osseous metastases. Radiographic monitoring of therapeutic response. Oncology 35:274
Wulff HB (1939) Radiological treatment of skeletal metastases in mammary cancer. Acta Radiol 20:40
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Libshitz, H.I., Hortobagyi, G.N. Radiographic evaluation of therapeutic response in bony metastases of breast cancer. Skeletal Radiol 7, 159–165 (1981). https://doi.org/10.1007/BF00361858
Issue Date:
DOI: https://doi.org/10.1007/BF00361858